APOE and Alzheimer disease: Together these findings suggest that an EPA-dominant formula may provide some benefit in APOE*E4 carriers with no dementia and WMLs, and DHA-dominant formulas may benefit noncarriers of APOE*E4 with mild-to-moderate AD.